Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel With or Without Oblimersen in Hormone-Refractory Prostate Cancer
NCT00085228Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2004
- Primary completion
- Jan 2006
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 11
01
Overview
A Phase 2 trial of oblimersen in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Started Apr 2004; status: completed.
02
Drugs
oblimersen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00085228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085228.